Greater average vision gains observed with EYLEA® vs. ranibizumab in Year 11,a
A Cochrane network meta-analysis demonstrated that:1,b
- DME patients are 30% more likely to gain ≥3-lines with EYLEA vs. ranibizumab in Year 1
- All efficacy outcomes significantly favoured EYLEA over ranibizumab in Year 1
“The difference between aflibercept and ranibizumab was consistent with indirect evidence based on studies that mostly used ranibizumab 0.5 mg, suggesting no dose effect”1,a
a This Cochrane meta-analysis included data from Protocol T where the dose of ranibizumab tested was 0.3 mg (US-approved dosage), while the ex-US dosage of ranibizumab is 0.5 mg. The treatment regimen tested in Protocol T was not the label regimen for either EYLEA or ranibizumab.
b Meta-analysis using Cochrane methods (based on a search of databases conducted in April 2017) of RCTs with anti-VEGF agents in DME patients, focused on the three most commonly used drugs: EYLEA, ranibizumab and unlicensed bevacizumab. The analysis included 24 studies and 6007 eyes in total. 17 studies (4031 eyes) were assessed for VA data.
c Bevacizumab is not licensed for the treatment of DME.
DME, diabetic macular edema; RCT, randomized controlled trial; VA, visual acuity; VEGF, vascular endothelial growth factor.
- Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:CD007419.